Sasame HA, Boyd MR
Key Ingredients: Water, Glycerin, Dipropylene Glycol, Propanediol, Hippophae Rhamnoides Water, Caprylic/Capric Triglyceride, PPG-13-Decyltetradeceth-24, Hydroxyacetophenone, Caprylyl Glycol, Carbomer, Tromethamine, Hydrogenated Lecithin, Glutathione(600 ppm), Cetearyl Alcohol, 1,2-Hexanediol, Disodium EDTA, Stearic Acid, Dipotassium Glycyrrhizate, Terminalia Ferdinandiana Fruit Extract, Butylene Glycol, Lecithin, Pentylene Glycol, Acetyl Glutamine, Sodium Hyaluronate, Polyglyceryl-10 Stearate, Panthenol, Folic Acid, Bacillus/Soybean Ferment Extract, Oligopeptide-1, Hexapeptide-11, Oligopeptide-2, Oligopeptide-3, Sodium Ascorbyl Phosphate, Hydrolyzed Pea Protein, Madecassoside, Phytosterols, Squalane, Olea Europaea (Olive) Fruit Oil, Tocopherol, Niacinamide, Hyaluronic Acid, Hydrolyzed Hyaluronic Acid, Hydroxypropyltrimonium Hyaluronate, Hydrolyzed Sodium Hyaluronate, Potassium Hyaluronate, Ceramide NP, Butyrospermum Parkii (Shea) Butter, Ethylhexylglycerin, Biotin, Sodium Hyaluronate Crosspolymer, Pyridoxine, Cyanocobalamin, Riboflavin, Thiamine HCl, Retinol, Bioflavonoids, Sodium Acetylated Hyaluronate, Menadione, Acetyl Hexapeptide-8, Copper Tripeptide-1, Palmitoyl Pentapeptide-4, Linoleic Acid, Beta-Carotene, Fragrance
Quercetin attenuates oxidative damage by stimulating Nrf2 translocation to the nucleus and concurrently inhibiting NF-Bmediated inflammatory signaling, which together mitigate ROS-induced apoptosis (86, 87)
0.5 and 1mg sermorelin acetate for subcutaneous injection, which was FDA approved in 1997 for therapy in children with idiopathic short stature
